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Abstract
Background: Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal
residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different
treatment approaches and regardless of the line of therapy.
Methods/design: GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) is a
seamless phase II/III, multi-centre, randomised, controlled, open, parallel-group trial for patients with CLL who have
recently responded to chemotherapy. Participants will be randomised to receive either obinutuzumab (GA-101)
consolidation or no treatment (as is standard). The phase II trial will assess safety and short-term efficacy in order to
advise on continuation to a phase III trial. The primary objective for phase III is to assess the effect of consolidation
therapy on progression-free survival (PFS). One hundred eighty-eight participants are planned to be recruited from
forty research centres in the United Kingdom.
Discussion: There is evidence that achieving MRD eradication with alemtuzumab consolidation is associated with
improvements in survival and time to progression. This trial will assess whether obinutuzumab is safe in a
consolidation setting and effective at eradicating MRD and improving PFS.
Trial registration: ISRCTN, 64035629. Registered on 12 January 2015.
EudraCT, 2014-000880-42. Registered on 12 November 2014.
Keywords: Chronic lymphocytic leukaemia (CLL), Obinutuzumab, GA-101, Consolidation, Phase II/III trial, Minimal
residual disease (MRD), Randomised controlled trial (RCT)
Background
Chronic lymphocytic leukaemia (CLL) is the most com-
mon adult leukaemia. The CLL8 trial [1, 2] has shown
that even though almost double the number of patients
receiving fludarabine, cyclophosphamide and rituximab
(FCR) achieved minimal residual disease (MRD) negativ-
ity (defined as <0.01% CLL cells) compared with those
receiving fludarabine and cyclophosphamide, once low-
level MRD was achieved, both arms showed the same
prognostic significance. This indirectly implies that the
depth of the remission may be more important than the
type of treatment given to attain that remission. Attain-
ment of MRD negativity has also been demonstrated as
an independent predictor of overall survival (OS) and
progression-free survival (PFS) even with a variety of dif-
ferent treatment approaches and regardless of the line of
therapy [3].
The researchers in the U.K. National Cancer Research
Institute (NCRI) CLL207 phase II trial [4] assessed
whether participants with low levels of disease could
attain MRD negativity following consolidation therapy
with alemtuzumab. The results showed good efficacy,
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with 39 (83%) of 47 participants who were consolidated
attaining MRD negativity. Overall, 38% remained MRD-
negative in the peripheral blood 6 months after therapy,
which may be the true MRD-negative population because
this represents the time for redistribution of the disease
among various compartments following antibody treat-
ment. After a median follow-up of 44 months, the partici-
pants who were MRD-negative 6 months after treatment
had a significantly increased PFS time compared with those
participants who were MRD-positive, with a median PFS at
3 years of 94.4% in MRD-negative participants compared
with 60.0% in MRD-positive participants (p = 0.004). How-
ever, alemtuzumab had a significant toxicity profile, with 22
serious adverse event (SAEs), 4 of which were clinically
unacceptable (1 pneumocystis pneumonia, 1 parainfluenza-
related death and 2 Epstein-Barr virus-related transformed
diseases), reported in 17 (36.2%) participants.
Obinutuzumab (GA-101) is a novel monoclonal anti-
body and has been shown to have greater efficacy in CLL
than previous anti-CD20 antibodies [5, 6], with reports of
MRD negativity when used to treat progressive CLL. In
addition, because the cells targeted by obinutuzumab are
B cells rather than all lymphocytes (including T cells),
obinutuzumab is likely to be significantly less immuno-
suppressive than alemtuzumab. The study of obinutuzu-
mab within the clinical trial setting has demonstrated a
rapid response in peripheral blood lymphocytosis, with
early reports of patients achieving MRD negativity with
obinutuzumab [7–9].
Rationale for therapeutic study
MRD-negative patients have a survival advantage in
comparison to MRD-positive patients, regardless of the
approach used to achieve MRD negativity. This is a
seamless phase II/III randomised trial in which we will test
whether consolidation with obinutuzumab to eradicate
MRD leads to prolonged PFS.
Methods/design
Trial design
This is a seamless phase II/III, multi-centre, randomised,
controlled, open, parallel-group trial for patients with
CLL who have recently responded to chemotherapy.
Patients with detectable MRD (MRD-positive) will be
randomised to receive either consolidation therapy with
obinutuzumab or no consolidation therapy (as is cur-
rently standard) (Fig. 1). The consolidation treatment
period is approximately 3 months. Participants who are
MRD-negative at baseline will be followed but not ran-
domised. A schedule of enrolment, interventions and
assessments is provided in Figs. 2 and 3, and a populated
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) checklist for this article is also
provided (Additional file 1).
Trial objectives
The trial has a seamless phase II/III design with separate
primary objectives for each phase (Fig. 4). The primary
objectives in phase II are to determine the rate of achiev-
ing MRD negativity at two pre-defined stages and assess
the safety of obinutuzumab in a consolidation setting. The
primary objective in phase III is to compare consolidation
therapy with obinutuzumab against no consolidation ther-
apy with respect to PFS in participants who responded to
previous therapy with a complete remission (CR) or good
partial remission (PR) with low levels of MRD.
The following are secondary objectives:
 To assess the eradication of detectable MRD, OS
and time to next treatment following consolidation
therapy with obinutuzumab
 To compare OS following consolidation therapy
with obinutuzumab against no consolidation therapy
 To compare time to next treatment for
obinutuzumab consolidation against no
consolidation
 To evaluate response rate, defined as CR or PR by
International Workshop on Chronic Lymphocytic
Leukemia criteria [10], following consolidation
therapy with obinutuzumab
 To evaluate and compare PFS and OS in
participants who are and who become
MRD-negative
 To assess the safety and toxicity of obinutuzumab
 To assess quality of life (QoL)
Trial population
Patients who are eligible for the trial must be at least
18 years old, have previous confirmation of CLL, have
undergone between one and three regimens of chemother-
apy previously ending between 3 and 24 months before
enrolment, have a peripheral B-cell count of <5 × 109/L,
have a response to the most recent chemotherapy treat-
ment for CLL with PR, complete remission with incom-
plete marrow recovery (CRi) or CR. The patient must also
be capable of giving written consent and have a World
Health Organisation (WHO) performance status of 0 or 1.
Patients with any of the following characteristics are
excluded from the trial: disease progression after response
to last therapy, active infection, previous anaphylaxis to
monoclonal antibodies, previous treatment with obinutuzu-
mab, central nervous system involvement in CLL, mantle
cell lymphoma, other severe concurrent diseases or mental
disorders that could interfere with their ability to
participate in the study (including moderate or worse
cardiac diseases), known HIV positivity, positive serology
for hepatitis B or C virus, persisting severe pancytopenia
(neutrophils <0.5 × 109/L or platelets <50 × 109/L) or
transfusion-dependent anaemia, vaccination with a live
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virus within 28 days, active haemolysis (patients with
haemolysis controlled with prednisolone at a dose 10 mg
or less per day can be entered into the trial), creatinine
and bilirubin less than two times the upper limit of nor-
mal, previously treated with an allogeneic stem cell trans-
plant, pregnant or lactating women, or women/men who
are capable of conceiving children and who are unwilling
to use appropriate medically approved contraception
during and for 18 months after receiving treatment.
Once participants provide consent for the trial, per-
ipheral blood will be tested for MRD. Patients who are
MRD-negative will not be eligible for randomisation
but will still be followed annually for MRD. Patients
who are MRD-positive will have bone marrow and
Fig. 1 Trial flow diagram. BM Bone marrow, CLL Chronic lymphocytic leukaemia, CTRU Leeds Clinical Trials Research Unit, HMDS Haematological
Malignancy Diagnostic Service, MRD Minimal residual disease, QoL Quality of life
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trephine samples tested centrally to confirm MRD level
in the aspirate, a stratification factor for randomisation.
To be randomised, participants must have an MRD-
positive peripheral blood sample between 3 and
24 months since completing the last treatment for CLL
and be confirmed as MRD-positive in the bone marrow.
Participants must also have clinically and radiologically
confirmed absence of lymphadenopathy (largest lymph
node 1.5 cm or less in minimum diameter).
Sample size
The overall sample size of the trial is powered for the
phase III primary endpoint of PFS. An internal literature
review investigating patients who have received up to
Fig. 2 Schedule of enrolment, interventions and assessments for participants who are suitable for randomisation. MRD Minimal residual disease,
PFS Progression-free survival. 1To be performed after the analysis of peripheral blood and only in participants whose peripheral blood is MRD
positive. 2 To be performed within 4 weeks of randomisation and before treatment is started. 3Only for participants randomised to obinutuzumab
and if appropriate clinically. 4Only required for participants randomised to treatment with obinutuzumab. 5Serum immunoglobulins and
electrophoresis only. 6Tested Centrally
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three lines of previous therapy of any type and who
responded to their most recent therapy with at least a PR
suggested that 3 years is a reasonable estimate for median
PFS in the control population (i.e., no consolidation), which
translates to approximately 2 years from the time the par-
ticipants are randomised (because it will be 3–24 months
after previous therapy). An important clinical improvement
would be an increase in median PFS from 2 to 3.3 years, a
relatively large improvement, because consolidation is given
at a time when patients would otherwise be in remission
and treatment-free. The trial is powered to test the null hy-
pothesis of no difference in PFS between the treatment
arms, with a two-sided 5% level of significance and 80%
power. Assuming 3 years of recruitment, 3 years of follow-
up and allowing for a 5% drop-out rate, 188 participants
are required (94 per arm) in order to observe 120 progres-
sion/death events. Losses to follow-up for the primary end-
point are expected to be extremely uncommon due to the
short treatment duration and straightforward and regular
follow-up schedule. A formal interim analysis on PFS will
be carried out and reported to the data monitoring and eth-
ics committee (DMEC) when half the required number of
events have been observed (60 events).
The O’Brien and Fleming alpha-spending function
[11] will be used to adjust for multiple testing to con-
serve the overall type I error, which recommends that
the interim results be compared with a p value of 0.005,
and the final analysis results are then compared with a
p value of 0.047.
Because obinutuzumab has not previously been used in
a consolidation setting, the short-term endpoint of MRD
negativity will be assessed to determine whether continu-
ation to the phase III part of the trial is worthwhile.
Because it may take up to 9 months from recruiting the
last participant to the time of analysis to determine their
MRD response, there will be a two-stage phase II design
to allow the first stage to be reviewed as early as possible
and prior to the completion of recruitment to the second
stage (Fig. 4). It is not planned to pause recruitment to
wait for the phase II outcomes, but the DMEC, on review
of the safety and early efficacy data, can choose to imple-
ment this should they feel it necessary.
Simon’s two-stage optimal design [12] will be used
to set stopping bounds at each stage of the analysis
(Fig. 4). A negativity rate above 35% would deem the
therapy active, and a success rate below 15% would
deem the therapy inactive. Participants randomised to
consolidation therapy with obinutuzumab who receive
at least 4 weeks of treatment will be included in the
phase II populations. With a 10% significance level
and 80% power, the trial will continue after the first
stage if, among the first nine participants, at least two
(22%) achieve MRD negativity. The trial will continue
after the second stage into the phase III part of the
trial if, among the first 23 participants, at least 6
(26%) achieve MRD negativity. Patients recruited
during phase II will contribute to the final phase III
target of 188 patients.
Fig. 3 Schedule of enrolment, interventions and assessments for participants who are MRD-negative by blood analysis. CT Computed
tomography, MRD Minimal residual disease, WHO World Health Organisation. 1If appropriate clinically. 2Tested Centrally
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Recruitment and consent
Participants will be recruited from approximately 40
research centres within the United Kingdom under the
guidance of the NCRI CLL sub-group. The recruitment
target requires that 188 participants be recruited into
the trial, 94 in each arm.
Fig. 4 Statistical design. CT Computed tomography, MRD Minimal residual disease, WHO World Health Organisation
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Patients will be approached during standard clinic visits
for management of CLL and provided with verbal and
written details about the trial. Informed consent will be
collected by principal investigators and co-investigators at
the participating hospitals before any trial-specific investi-
gations. Participants are able to withdraw from treatment
and follow-up at any stage of the trial. Participants will
also be approached for the UK CLL Trials Biobank, as
discussed in the “Sub-studies” section below.
Randomisation
Following confirmation of eligibility and informed
consent, MRD-positive participants will be randomised
into the trial by an authorised staff member at the trial
research site. Randomisation will be performed centrally
using the Leeds Clinical Trials Research Unit (CTRU)
automated 24-hour telephone registration and random-
isation system. Participants will be randomised on a 1:1
basis to receive either obinutuzumab consolidation or
no treatment. Participants will be informed of their
treatment allocation in this open study.
A computer-generated minimisation program that
incorporates a random element will be used to ensure
treatment groups are well-balanced for the following
participant characteristics: bone marrow MRD level at
entry (≤0.3%, >0.3%), number of lines of previous ther-
apy (one, more than one), age group (≤65, >65 years),
sex (male, female), Binet stage of disease prior to most
recent CLL therapy (A progressive or B, C) and previous
rituximab (yes, no).
Protecting against bias
This trial cannot be blinded, because the two treatment
arms are substantially different. Treating consultants
need to be aware of the drugs being administered to be
able to treat reactions to treatment accordingly. The trial
researchers will use an automated randomisation service
incorporating randomisation by minimisation, and ana-
lyses will be done on an intention-to-treat (ITT) basis.
The trial is administered by the chief and principal
investigators and the CTRU in accordance with good
clinical practice (GCP) guidelines. The assessment of
response in the peripheral blood and the bone marrow
for MRD will be centralised in a single laboratory,
thereby providing standardisation for all assessments.
Baseline assessments
Assessments to be performed prior to the participant
starting treatment are a complete physical examination,
WHO performance status, serology for hepatitis B and
C virus, local haematology and biochemistry, a preg-
nancy test (for women of childbearing potential), an
assessment of disease using blood, bone marrow aspirate,
trephine, computed tomographic (CT) scan and QoL
questionnaires. See the schedule of enrolment, interven-
tions and assessments in Figs. 2 and 3. Some of these
assessments will have already been carried out to confirm
eligibility for randomisation. Where these assessments are
done within 4 weeks of starting treatment, the eligibility
assessments will be used for baseline. Where they fall
outside this time frame, they will be repeated for baseline.
Intervention
Participants randomised to obinutuzumab consolidation
will receive 100 mg of intravenous (IV) obinutuzumab
on day 1 and 900 mg on day 2. The remaining course of
treatment will be 1000 mg IV on days 8, 15, 22 (weekly),
36, 50, 64 and 78 (2-weekly). Participants randomised to
no consolidation therapy will receive no treatment.
Participants will be assessed for their suitability for treat-
ment within 1 week before each obinutuzumab treatment.
At minimum, tests will be performed to ensure that dose
delays or reductions are implemented and that concomi-
tant medications are administered as per protocol.
Prior to medication, analgesic/antipyretic (equivalent
to 1000 mg of paracetamol) will be administered before
each treatment. Antihistamine (equivalent to 10 mg of
cetirizine) will be administered prior to days 1 and 2 of
treatment and for remaining treatments for participants
with an infusion-related reaction (IRR) (Common Ter-
minology Criteria for Adverse Events [CTCAE] [13]
grade 1 or higher) to the previous infusion. Corticoster-
oid infusion (equivalent to 100 mg of prednisolone) will
be administered for days 1 and 2 and for participants
with a grade 3 IRR with the previous infusion or partici-
pants with a lymphocyte count >25 × 109/L before treat-
ment. No concomitant cytotoxic agents, radiotherapy or
vaccination with live viruses should be given.
Management of toxicity
IRRs
For grade 4 IRRs, the infusion will be stopped and
therapy discontinued. For grade 3 IRRs, the infusion will
be temporarily interrupted and symptoms treated. Upon
resolution of grade 3 symptoms, infusion will be restarted
at no more than half the rate being used at the time that
the IRR occurred, and, if the participant does not experi-
ence any IRR symptoms, infusion rate escalation may be
resumed at the increments and intervals appropriate for
the treatment dose. For grades 1–2 IRRs, the infusion rate
will be reduced and symptoms treated. Upon resolution of
symptoms, the infusion will be continued, and, if the par-
ticipant does not experience any IRR symptoms, infusion
rate escalation may resume at the increments and inter-
vals appropriate for the treatment dose. Treatment may
be discontinued due to poor tolerability/toxicity at the
discretion of the treating physician. The guidance in the
next sub-sections is applied to manage toxicity.
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Haematological toxicity
Participants who experience grade 3 thrombocytopenia
(platelets <50 × 109/L) should be withdrawn from obinu-
tuzumab because this toxicity is potentially a result of
obinutuzumab. Participants who experience grade 3/4 neu-
tropenia (neutrophils <1.0/<0.5 × 109/L) should be closely
monitored. The use of granulocyte colony-stimulating
factor is recommended to maintain the neutrophil count
above 1.0 × 109/L. Treatment with obinutuzumab should
be delayed until neutrophils are > 1.0 × 109/L.
Non-haematological toxicity
If hypersensitivity to obinutuzumab occurs (typically
occurring after previous exposure to obinutuzumab), the
infusion should be stopped and treatment permanently
discontinued. Participants with a known immunoglobu-
lin E-mediated hypersensitivity to obinutuzumab should
not be treated. Obinutuzumab should not be adminis-
tered in the presence of a severe infection. Prophylactic
therapy aimed at preventing a recurrence of a diagnosed
infection should be instituted if clinically indicated. For
treatment of tumour lysis syndrome, electrolyte abnor-
malities should be corrected, renal function and fluid
balance monitored and supportive care administered,
including dialysis as indicated.
Progressive multifocal leukoencephalopathy (PML)
Cases of progressive multifocal leukoencephalopathy
(PML) have been reported in patients treated with anti-
CD20 antibodies, including obinutuzumab. Treatment
with obinutuzumab should be withheld during the inves-
tigation of potential PML and permanently discontinued
in the event of a confirmed diagnosis.
Hypotension
Hypotension may occur during obinutuzumab infusions.
Therefore, withholding of antihypertensive treatments
should be considered for 12 hours before the obinutuzu-
mab infusion, during the obinutuzumab infusion and for
the first hour after administration. Patients with a
history of cardiac disease should be monitored closely. A
participant should permanently discontinue obinutuzumab
treatment in the following situations:
 For grade 4 infusion-related symptoms, patient
should be withdrawn immediately, and treatment
must be discontinued permanently
 For grade 3 infusion-related symptoms at re-
challenge, patient must be withdrawn immediately,
and treatment must be discontinued permanently
 Grade 3 or 4 cytopenia that has not resolved to
grade 2 or lower and delays treatment of the next
dose by 4 weeks
 Grade 2 or higher non-cytopenic toxicity that does
not resolve to grade 1 or lower/baseline and delays
treatment of the next dose by 4 weeks
Follow-up
A formal assessment of disease response will be made
6 months post-randomisation (or at least 2 months after
last treatment if treatment has been delayed). As shown
in Figs. 2 and 3, this will require a physical examination
and local laboratory tests; the collection of blood, bone
marrow aspirate and trephine samples (for participants
randomised to treatment, and trephine only where
clinically indicated); CT scan (where clinically indicated);
and assessment of QoL.
Follow-up visits to assess ongoing disease response
and survival will be made every 3 months between 9 and
36 months post-randomisation. Participants who are
MRD-negative post-consolidation treatment will also
have blood collected at 12, 24, 36 and 48 months post-
randomisation. All participants will be followed annually
for survival until death. MRD blood assessments will
end once a participant becomes MRD-positive.
All trial MRD testing will be carried out centrally by the
Haematological Malignancy Diagnostic Service at Leeds
Teaching Hospitals National Health Service (NHS) Trust
using the harmonised European Research Initiative on
CLL method [14] to ensure standardisation of reporting.
Participants who are MRD-negative at baseline will have
blood collected for MRD analysis at 12, 24 and 36 months
post-registration. No further samples are collected if the
participant becomes MRD-positive.
Safety reporting
Adverse events (AEs) are any untoward medical occur-
rences in a participant who has been administered a
medicinal product and do not necessarily have a causal
relationship with treatment and are related to any dose ad-
ministered of any trial treatment. These can be defined as
any unintentional, unfavourable clinical sign or symptom;
any new illness or disease; the deterioration of existing
disease or illness; or any clinically relevant deterioration in
any laboratory assessments or clinical tests. AEs will be
recorded from randomisation until 30 days after the last
dose of trial treatment (or 4 months post-randomisation
for participants randomised to no treatment) or disease
progression, and they will be evaluated for duration, inten-
sity and causal relationship with the trial medication
according to the CTCAE version 4.03.
SAEs and serious adverse reactions (SARs) are events
that are fatal or life-threatening, require or prolong
hospitalisation, are significantly or permanently disabling
or incapacitating, constitute a congenital anomaly or a
birth defect, or any other important medical event. SARs
are SAEs that are deemed to be possibly related to any
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dose administered of any trial treatment. Suspected
unexpected serious adverse reactions (SUSARs) are
SARs that are not listed in the reference safety informa-
tion for that medicinal product. SAEs will be collected
from randomisation until 3 months after the last dose of
treatment (or 6 months post-randomisation for partici-
pants randomised to no consolidation therapy). SARs and
SUSARs should be reported from the start of treatment
and for the duration of the trial. Several adverse events of
special interest (AEoSI) are also to be collected until the
participant begins the next line of therapy. AEoSI are
tumour lysis syndrome (serious and non-serious), serious
IRRs, serious infections and serious neutropenia.
Data collection
Data will be collected on paper case report forms and
entered into a validated trial database by CTRU. A valid-
ation check program will be incorporated into the trial
database to verify the data, and discrepancy reports will
be generated for resolution by the investigator. Priority
validations will be incorporated into the validation
programme to ensure that any discrepancies related to
participant rights or safety are expedited to sites for
resolution. Data will be monitored for quality and com-
pleteness by the CTRU. Missing data will be chased until
received, confirmed as not available or the trial is at
analysis. The CTRU/sponsor will reserve the right to inter-
mittently conduct source data verification exercises on a
sample of participants, which will be carried out by staff
from the CTRU/sponsor. Source data verification will in-
volve direct access to participant notes at the participating
hospital sites and the central collection of copies of consent
forms and other relevant investigation reports. Data will be
held on a secure server at the University of Leeds, and
paper case report forms will be stored in a locked unit,
with both being accessible only by authorised trial staff.
Statistical methods and analysis
Statistical analysis is the responsibility of the CTRU
statisticians, and a final statistical analysis plan will be
written and signed off before any analysis takes place.
The primary endpoint of the phase II analyses will be
carried out on participants randomised to obinutuzumab
who receive at least 4 weeks of treatment. The phase III
analyses will be conducted on the ITT population, where
participants will be included according to the treatment
to which they were randomised. A per-protocol analysis,
where participants will be included according to the
treatment they received, will be considered for the phase
III primary endpoint of PFS if there are a considerable
number of protocol violators. The safety population will
consist of all participants according to the treatment to
which they were randomised.
Primary endpoint analyses
The phase II primary endpoint of MRD negativity in each
stage of the phase II part of the trial will be assessed once 9
and 23 participants have received at least 4 weeks of obinu-
tuzumab treatment and been followed until 6 months
post-randomisation. The phase III primary endpoint of
PFS will be assessed once 120 events (progressions/deaths)
have been observed overall. A formal interim analysis will
be carried out when 60 events have been observed overall
in order to allow large differences between the trial arms to
be reported early (Fig. 4). PFS is defined as the time from
randomisation to first documented evidence of progression
or death. Participants not having progressed or died or
who are lost to follow-up at the time of the phase III ana-
lyses will be censored at the last date they were known to
be alive and progression-free. For the analysis of
primacy, we will use a Cox proportional hazards
model [15] to compare the trial arms, adjusting for the
minimisation factors, to calculate the HR and corre-
sponding 95% CIs. The p value to assess for statistical
significance will be compared with 0.047 to account
for the formal interim analysis. In addition, median sur-
vival estimates with corresponding 95% CIs, as well as
Kaplan-Meier curves [16], will be produced by trial arm.
Secondary endpoint analyses
All secondary endpoint analyses comparing randomised
participants will be assessed at the same time as the pri-
mary endpoint of PFS. The proportion of participants with
undetectable MRD will be summarised (with 95% CIs) for
participants randomised to consolidation therapy with
obinutuzumab at 6 months post-randomisation and then at
every time point at which MRD is assessed. CR, CRi and
overall response (at least a PR) will be summarised (with
95% CIs) for participants randomised to consolidation ther-
apy with obinutuzumab at 6 months post-randomisation
and then at every time point at which response is assessed.
OS and treatment-free survival (TFS) (i.e., time from
randomisation to next treatment or death) will both be
assessed using Cox proportional hazards models to com-
pare trials arms, adjusting for the minimisation factors.
Kaplan-Meier curves, 95% CIs and median survival esti-
mates will also be produced for both analyses by trial arm.
Participants who are registered and eligible but MRD-
negative and so not randomised will also be followed for
progression and death and will contribute to three
secondary endpoint analyses. PFS, OS and duration of
MRD negativity (i.e., time from end of most recent ther-
apy for CLL to date of progression or death; date of
death; or date of MRD relapse or death, respectively) will
be assessed using Cox proportional hazards models to
compare those who are MRD-negative at registration
with those who become MRD-negative following con-
solidation therapy with obinutuzumab.
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Occurrence and frequency of SUSARs, SARs, SAEs,
AEoSI, AEs and treatment-related deaths will be sum-
marised by trial arm and overall. In addition, all events
will be summarised by maximum CTCAE grade reported
and seriousness criteria, and all serious events will be sum-
marised by Medical Dictionary for Regulatory Activities
(MedDRA) System Organ Class, by trial arm and overall.
Mean QoL scores and 95% CIs, adjusted for the baseline
score, will be calculated for all domains of the European
Organisation for Research and Treatment of Cancer
(EORTC) Core Quality of Life Questionnaire (QLQ-C30)
and the CLL-specific module (EORTC QLQ-CLL16) for
each trial arm and at each assessment time point and
overall. Wilcoxon’s rank-sum tests will be used to com-
pare the change in score for the trial arms from baseline
to each time point.
Interim reports
An independent DMEC will review the safety and ethics
of the trial while participants are receiving trial treatment,
reviewing unblinded safety updates at 3-monthly intervals,
and more detailed unblinded reports at yearly intervals.
The phase II analyses on the proportion of participants
with undetectable MRD will be reviewed by the DMEC
when 9 and 23 participants have received at least 4 weeks
of consolidation therapy with obinutuzumab and been
followed until 6 months post-randomisation.
A formal interim analysis on the phase III primary end-
point of PFS will be reviewed by the DMEC when half the
required number of events have been observed (60 events).
The DMEC, in light of the interim data, and of any advice
or evidence they wish to request, will advise the trial steer-
ing committee (TSC) if there are any concerns or reasons
that the trial should not continue or if they believe that the
trial results should be shared further.
Sub-studies
Trial participants will also be invited to take part in the
UK CLL Trials Biobank at the University of Liverpool.
Participants will be approached at baseline with a separ-
ate consent form (research ethics committee reference
14/NW/1014), and biological samples will be sent to the
University of Liverpool.
Trial organisation and administration
The trial was developed by the GALACTIC Trial Manage-
ment Group (TMG) with the support of the UKCLL/
NCRI CLL Clinical Trials Sub-Group. The trial is funded
by Cancer Research UK and Roche. The trial is sponsored
by the University of Leeds (R&D Office, 34 Hyde
Terrace, Leeds, LS2 9LN, UK), co-ordinated by the
CTRU, University of Leeds, and is registered with two
trial databases (ISRCTN64035629, EudraCT 2014-000880-
42). The trial will be conducted in accordance with the
principles of GCP in clinical trials, as applicable under U.K.
regulations, the NHS Research Governance Framework
and through adherence to CTRU standard operating
procedures. The CTRU/sponsor has systems in place to
ensure that serious breaches of GCP or the trial protocol
are identified and reported. Ethical approval has been
obtained from the National Research Ethics Service
Committee Yorkshire & Humber – Leeds East (reference
14/YH/1199). A sample of data will be assessed by on-site
source data verification by the CTRU, and this is not
independent from the sponsor. The University of Leeds
will be liable for negligent harm caused by the design of
the trial. No additional compensation for clinical negli-
gence will be provided for trial participants over that
which is available to NHS patients. Obinutuzumab was
provided by the sponsor only for the duration of protocol
treatment, and subsequent treatment will be provided as
per standard care.
A core project team, a TMG, a TSC and a DMEC have
been established. The independent DMEC will review
the safety and ethics of the trial, as overseen by the
independent TSC. The TSC will monitor trial progress
and the overall direction. Three-monthly interim safety
reports are presented to the DMEC, with a full review
done annually. The DMEC will also review SARs and
SUSARs that result in death in real time. This commit-
tee, in light of the interim data and of any advice or evi-
dence they wish to request, will advise the TSC if there
are any concerns or reasons that the trial should not
continue. The results of the study will be published in
peer-reviewed publications and will be presented at rele-
vant national and international conferences. There are no
plans to use professional writers for presenting the out-
comes of this trial. Any protocol changes are disseminated
by the CTRU to the relevant parties. A SPIRIT checklist
was prepared for this article (Additional file 1). A SPIRIT
diagram was prepared for this article (Figs. 2 and 3).
Discussion
Recruitment for the GALACTIC trial has been challenging.
Recruitment numbers provided during feasibility assess-
ment were significantly higher than observed during trial
recruitment. We believe this was due partly to improved
first- and second-line treatments providing a more durable
remission, resulting in fewer MRD-positive patients at 3–24
months post-treatment. With more recent targeted therap-
ies, treatment now continues for much longer than the
standard 6-month period (with FCR, for example). This is
likely to have reduced the number of eligible patients.
Whilst acceptance of the trial by patients has been
high, the prospect of returning to hospital for further
treatment is seen as an additional burden for many, par-
ticularly those who would be required to travel a long
way to their nearest hospital. Because the trial protocol
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represents an additional cost for the NHS Trust com-
pared with standard treatment, it has been difficult to
enrol centres into the study, despite wide support from
investigators. The aim of the findings of the GALACTIC
trial is to compare consolidation with obinutuzumab
with no consolidation with respect to PFS in patients
who have responded to previous therapy with a CR or
good PR with low levels of MRD.
Trial status
The trial opened to recruitment in February 2015 using
protocol version 2.0 (registered 30 October 2014) and
closed to recruitment in February 2017.
Additional files
Additional file 1: SPIRIT checklist. (DOC 121 kb)
Additional file 2: List of participating centres. (PDF 153 kb)
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